Overview
OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
Status:
Completed
Completed
Trial end date:
2014-11-01
2014-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of chronic allergic conjunctivitisPhase:
Phase 2Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Ocular Therapeutix, Inc.Collaborator:
ORA, Inc.Treatments:
Dexamethasone
Criteria
Inclusion Criteria:- Has a positive history of ocular allergies and a positive skin test reaction to a
perennial allergen and a seasonal allergen
- Has a positive bilateral CAC reaction to a perennial allergen within minutes of
instillation
Exclusion Criteria:
- History of ocular surgical intervention within the past 3 months
- Presence of an active ocular infection or positive history of an ocular herpetic
infection at any visit
- Use any of the following disallowed medications during the period indicated